Inhibikase Therapeutics, Inc. - Common Stock (IKT)
1.9600
-0.1500 (-7.11%)
Inhibikase Therapeutics is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly those related to Parkinson's disease
The company aims to address the underlying mechanisms of these conditions by harnessing its proprietary drug discovery platform to identify and develop compounds that can improve patient outcomes. Their research is centered around the modulation of key biological pathways implicated in neurodegeneration, with the goal of offering new treatment options that can enhance the quality of life for individuals affected by these debilitating disorders.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Inhibikase Therapeutics shares are trading higher by 50% during Wednesday's session. The company announced the pricing of an approximately $110 million private placement financing.
Shares of Dermata Therapeutics, Inc. (NASDAQDRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. Dermata Therapeutics shares jumped 57.3% to $0.9601 in pre-market trading.
Shares of bluebird bio, Inc. (NASDAQBLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
